Research Spotlight: Antiretroviral Nanoparticles: an Extended Drug Delivery Modality

• Davey RT Jr, Bhat N, Yoder C et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA96, 15109–15114 (1999).
   PubMed Web of Science ®Google Scholar
• Schrager LK , D‘SouzaP. Cellular and anatomical reservoirs and HIV-1 in patients receiving potent antiretroviral combination therapy. J. Am. Med. Assoc.280, 67–71 (1998).
   PubMed Web of Science ®Google Scholar
• Gallant JE . Strategies for long-term success in the treatment of HIV infection. J. Am. Med. Assoc.283, 1329–1334 (2000).
   PubMed Web of Science ®Google Scholar
• Paterson DL , SwindellsS, MohrJet al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21–30 (2000).
   PubMed Web of Science ®Google Scholar
• Mascolini M , LanderBA, BoucherCA, RichmanDD, MellorsJW. Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV drug Resistance Workshop. Antivir. Ther.13, 1097–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Murri R , LepriAC, CicconiPet al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naïve patient study. J. Acquir. Immune Defic. Syndr. 41, 23–30 (2004).
   Web of Science ®Google Scholar
• McKinnon JE , MellorsJW, SwindellsS. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir. Ther.14, 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Koenig S , GendelmanHE, OrensteinJMet al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 1089–1093 (1986).
   PubMed Web of Science ®Google Scholar
• Persidsky T , GendelmanHE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J. Leukoc. Biol.74, 691–701 (2003).
   PubMed Web of Science ®Google Scholar
• Embretson J , ZupancicM, RibasJLet al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubating period of AIDS. Nature 362, 359–362 (1993).
   PubMed Web of Science ®Google Scholar
• Pantaleo G , GraziosiC, DemarestJRet al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355–358 (1993).
   PubMed Web of Science ®Google Scholar
• Ghosn J , ChaixML, PeytavinGet al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18, 1958–1961 (2004).
   PubMed Web of Science ®Google Scholar
• McGee B , SmithN, AweekaF. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clinical Trials7, 142–153 (2006).
   PubMed Web of Science ®Google Scholar
• Yeh RF , RezkNL, KashubaADet al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob. Agents Chemother. 53, 2367–2374 (2009).
   PubMed Web of Science ®Google Scholar
• Funderburg NT , MayneE, SiegSFet al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115, 161–167 (2010).
   PubMed Web of Science ®Google Scholar
• Engels EA , PfeifferRM, LandgrenO, MooreRD. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J. Acquire Immune Defic. Syndr.54, 78–84 (2010).
   PubMed Web of Science ®Google Scholar
• Kingsley JD , DouH, MoreheadJ, RabinowB, GendelmanHE, DestacheCJ. Nanotechnology: a focus on nanoparticles as a drug delivery system. J. Neuroimmune Pharmacol.1, 340–350 (2006).
   PubMed Web of Science ®Google Scholar
• Destache CJ , BelgumT, ChristensenK, ShibataA, SharmaA, DashA. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect. Dis.9, 198 (2009).
   PubMed Web of Science ®Google Scholar
• Destache CJ , BelgumT, ShibataA, DashA. In vivo levels of ritonavir (RTV), lopinavir (LPV), efavirenz (EFV) over time after intraperitoneal (IP) injection of antiretroviral (AR) PLGA nanoparticle (NP). (Abstract A1-1313). Presented at: 49th Interconference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Dou H , MoreheadJ, DestacheCJet al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358, 148–158 (2007).
   PubMed Web of Science ®Google Scholar
• Dou H , GrotepasCB, McMillanJMet al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuro-AIDS. J. Immunol. 183, 661–669 (2009).
   PubMed Web of Science ®Google Scholar
• Nowacek AS , McMillanJ, MillerR, AndersonA, RabinowB, GendelmanHE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol. (2010) (In Press).
   PubMedGoogle Scholar

Website

• WHO. HIV/AIDS Programme. Highlights 2008–2009. WHO, HIV/AIDS Dept. Geneva, Switzerland www.who.int.hiv (Accessed 14June2010)
   Google Scholar